Table 1

EGFR antibodies single agent versus best supportive care in patients with refractory mCRC

			n	RR (%)	PFS			OS
			n	RR (%)	Median	HR	p Value	Median	HR	p Value
	ITT population
	BSC		231	0	7.3 weeks	0.54	<0.001	NA	1.00	NS^*
	Panitumumab		232	10	8.0 weeks	0.54	<0.001	NA
	BSC		285	0	NA	0.68	<0.001	4.6	0.77	0.005
	Cetuximab		287	8	NA	0.68	<0.001	6.1
	K-ras population
	BSC	WT	219	0	7.3 weeks	0.45	<0.001
	Panitumumab	WT	218	17	12.3 weeks	0.45	<0.001
	BSC	mut	95	0	7.3 weeks	0.99	NS
Panitumumab trial 92% of ITTpopulation	Panitumumab	mut	76	0	7.4 weeks	0.99	NS
Cetuximab trial 69% of ITT population	BSC	WT		0	1.9 months	0.40	<0.001	4.8 mos	0.55	<0.001
	Cetuximab	WT		12,8	3.7 months	0.40	<0.001	9.5 mos	0.55	<0.001
	BSC	mut		0	1.8 months	0.99	NS	4.6 months	0.98	NS
	Cetuximab	mut		1,2	1.8 months	0.99	NS	4.5 months	0.98	NS

↵* Crossover design.
BSC, best supportive care; EGFR, epidermal growth factor receptor; ITT, intention to treat; mCRC, metastatic colorectal cancer; mut, mutated; NA, not available; NS, non-significant; OS, overall survival; PFS, progression-free survival; WT, wild type.